Financial Performance - Sales for the second quarter increased 3.0% to $20.8 billion compared to the same period in fiscal year 2025[5] - Gross profit increased 3.9% to $3.8 billion, with a gross margin of 18.3%, reflecting a 15 basis point increase[6] - Operating income decreased 2.8% to $692 million, while adjusted operating income increased 3.1% to $807 million[3] - Net earnings decreased 4.2% to $389 million, but adjusted net earnings increased 3.9% to $476 million[3] - Sales for the 13-week period ended December 27, 2025, were $20,762 million, an increase of 3.0% compared to $20,151 million for the same period in 2024[24] - Gross profit for the 26-week period ended December 27, 2025, was $7,693 million, up from $7,403 million in 2024, reflecting a growth of 3.9%[24] - Net earnings for the 26-week period ended December 27, 2025, were $866 million, a decrease of 3.3% from $896 million in the prior year[26] - Basic earnings per share for the 13-week period ended December 27, 2025, were $0.81, compared to $0.83 for the same period in 2024[24] - For the 26-week period, Sysco reported GAAP sales of $41,910 million, a 3.1% increase from $40,634 million in the prior year[36] - Diluted earnings per share (GAAP) decreased to $1.80, down 1.1% from $1.82[37] Cash Flow and Shareholder Returns - Cash flow from operations was $611 million, and free cash flow was $413 million for the first 26 weeks of fiscal year 2026[13] - The company returned $518 million to shareholders via dividends during the first 26 weeks of fiscal year 2026[13] - Free cash flow for the 26-week period ended December 27, 2025, was $413 million, up from $331 million in the prior year, reflecting an increase of $82 million[43] Sales Growth - U.S. Foodservice local case volume grew by 1.2%, contributing to overall positive case growth[1] - International Foodservice Operations sales increased 7.3% to $4.0 billion, with a gross profit increase of 9.5% to $832 million[11] - U.S. foodservice operations sales increased by $339 million, or 2.4%, reaching $14,383 million[38] - International foodservice operations sales grew by $271 million, or 7.3%, totaling $3,999 million[38] - Total Sysco sales rose by $611 million, or 3.0%, to $20,762 million[39] Operating Expenses - Operating expenses increased by 5.5% to $3,100 million, with adjusted operating expenses (Non-GAAP) at $2,985 million, reflecting a 4.1% increase[33] - Operating expenses for Total Sysco increased by 5.4% to $6,200 million, with adjusted operating expenses rising by 4.2% to $5,987 million[41] Debt and Leverage - Long-term debt stood at $12,440 million as of December 27, 2025, slightly up from $12,360 million as of June 28, 2025[25] - Total Debt (GAAP) stands at $13,590 million, with Net Debt (Non-GAAP) at $12,368 million[48] - The Net Debt to Adjusted EBITDA ratio (Non-GAAP) is 2.86, indicating the company's leverage relative to its earnings[48] Adjusted Metrics - Adjusted net earnings for fiscal 2026 were $1,028 million, a 3.1% increase from $997 million in fiscal 2025[37] - Adjusted EBITDA growth is considered a key measure of financial performance, with management emphasizing its importance for consistent period comparisons[44] - Adjusted EBITDA for the 13-week period, after certain item adjustments, increased to $1,001 million, reflecting a 3.3% rise from $969 million in the previous year[45] - Adjusted EBITDA for the 26-week period was $2,071 million, an increase of 1.7% compared to $2,037 million in the prior year[46] Strategic Focus - Sysco continues to focus on growth through acquisitions, excluding acquisition-related costs from its non-GAAP financial measures to enhance comparability[31] - The company reported a significant increase in acquisition-related costs, rising to $23 million from $8 million year-over-year, indicating ongoing strategic investments[45] - The impact of restructuring and transformational project costs was significant, with a total impact of $114 million on operating expenses for Total Sysco[41] - The impact of restructuring and transformational project costs in fiscal 2026 included $21 million in severance charges and $93 million in transformation initiative costs[37]

Revenue Performance - Total revenues decreased to $2,073,557 in 2025 from $3,496,405 in 2024, a decline of approximately 40.7%[435] - Service business revenue fell to $1,843,968 in 2025 from $3,091,903 in 2024, a decrease of about 40.3%[436] - Digital revenue decreased to $168,240 in 2025 from $327,802 in 2024, representing a decline of approximately 48.7%[437] - Rental revenue was $61,349 in 2025, down from $76,700 in 2024, a decrease of about 20.0%[438] - Related party service revenue for 2025 totaled $58,861, a decrease of 83.9% from $364,336 in 2024, representing 2% of total service revenue[461] Expenses and Losses - General and administrative expenses reduced to $3,818,580 in 2025 from $4,039,243 in 2024, a decrease of approximately 5.5%[448] - Loss from operations increased to $2,152,416 in 2025 compared to $969,278 in 2024, reflecting a rise of approximately 121.5%[441] - Net loss for 2025 was $2,982,333, significantly higher than the net loss of $725,827 in 2024, an increase of approximately 310.5%[454] - The company recorded net other expenses of $817,676 in 2025, compared to net other income of $247,890 in 2024[449] Related Party Transactions - Digital revenue from related parties in 2024 was $21,000, with 95% generated from the CEO, Mr. Lee[463] - Cost of service revenue to related parties increased to $14,642 in 2025 from $10,934 in 2024[464] - Related party G&A expenses decreased to $145,505 in 2025 from $149,817 in 2024[467] - Other income from related parties was $38,729 in 2025, down from $47,635 in 2024[471] - Interest income from related parties increased to $6,103 in 2025 from $5,073 in 2024[472] - Gain on disposal of related party investments was $39,800 in 2025, a significant decrease from $324,917 in 2024[474] Cash Flow and Financing - Cash balance decreased to $636,659 as of December 31, 2025, from $1,124,818 in 2024, a decline of 43.4%[499] - Net cash used in operating activities increased to $1,790,250 in 2025 from $1,360,454 in 2024[503] - Net cash provided by investing activities was $37,162 in 2025, a decrease from $601,277 in 2024, primarily due to lower proceeds from investment disposals[508][509] - Financing activities generated net cash of $1,234,025 in 2025, primarily from the sale of Common Stock in private placements totaling $1,235,000[510] - The company issued 1,050,000 shares of Common Stock in private placements in 2025, increasing total shares outstanding to 8,625,813[511] - In 2024, the company did not issue any shares, maintaining 7,575,813 shares outstanding as of December 31[512] Future Outlook - The company expects slight recovery in service business revenue as it explores new markets[435] - The company reported net cash used in operating activities over the past two years, indicating ongoing operational challenges[507] - The company is classified as a smaller reporting company and is not required to provide detailed market risk disclosures[513] Acquisitions - The acquisition of the remaining 40% shares of Forward Win International Limited was completed in April 2024, making it a wholly owned subsidiary[451] Non-Cash Expenses - Non-cash expenses for 2025 included depreciation and amortization of $240,147, impairment of property and equipment of $813,552, and impairment of goodwill of $6,035, totaling significant non-cash charges[505] - In 2024, non-cash expenses included depreciation and amortization of $245,921 and impairment of goodwill of $82,561, with total non-cash income from gains on disposal of investments amounting to $346,551[506]

Financial Performance - The company reported a net loss of $36.7 million for the year ended December 31, 2024, which decreased to $26.6 million for the year ended December 31, 2025, representing a reduction of 28%[402] - For the year ended December 31, 2025, the company reported a net loss of $26.6 million, with an accumulated deficit of $127.8 million as of the same date[411] - The company has an accumulated deficit of $127.8 million as of December 31, 2025[391] Expenses - Research and development expenses decreased by approximately $10.9 million, or 54%, from $20.0 million in 2024 to $9.1 million in 2025, primarily due to reduced drug development costs[403] - General and administrative expenses increased by $8.3 million, or 69%, from $12.1 million in 2024 to $20.4 million in 2025, driven by higher marketing and consulting costs[404] - Net cash used in operating activities was $31.3 million for the year ended December 31, 2025, primarily due to development costs and corporate expenditures[418] - The company incurred net cash used in investing activities of $12.1 million for the year ended December 31, 2025, mainly due to the purchase of marketable securities[421] Financing Activities - The company sold 3,123,537 shares of common stock at an average price of $6.51 per share, resulting in net proceeds of approximately $19.6 million[395] - The company entered into a sales agreement to offer and sell shares of common stock with an aggregate offering price of up to $100 million, resulting in net proceeds of approximately $45.2 million for the year ended December 31, 2025[410] - Net cash provided by financing activities was $46.5 million during the year ended December 31, 2025, primarily from sales under the sales agreement with Guggenheim Securities LLC[422] Future Plans and Expectations - The company plans to resubmit its New Drug Application (NDA) for oxylanthanum carbonate (OLC) to the FDA, with a target action date set for June 29, 2026[395] - The company expects significant increases in operating expenses as it advances product candidates through clinical development and seeks regulatory approval[391] - The company anticipates future revenue streams from collaboration or licensing agreements, as well as product sales[408] - The company plans to continue its drug discovery efforts and clinical trials, which will significantly influence future capital requirements[414] - The company expects to continue incurring losses and will need to raise additional capital for clinical trials and product development initiatives[413] - The company anticipates that its current cash will be sufficient to fund operations for more than 12 months from the date of the report[412] Market Context - The healthcare costs associated with acute kidney injury (AKI) exceed $9 billion annually in the U.S., highlighting a significant unmet medical need[389] - The company aims to leverage its management team's expertise and network to identify and develop new product candidates beyond kidney disease[386] Accounting Policies - The company accounts for stock-based compensation using the Black-Scholes option-pricing model, recognizing expenses over the requisite service period[429] Off-Balance Sheet Arrangements - The company has no off-balance sheet arrangements as of December 31, 2025[424]

Revenue Growth - Fourth Quarter Consolidated Net Revenues reached $58.80 million, a 131.8% increase year-over-year from $25.37 million in Q4 2024[2] - Net Revenues from Light Electric Vehicles (LEV) surged by 524.1% year-over-year to $12.92 million, compared to $2.07 million in Q4 2024[2] - Net Revenues from the Battery Raw Materials Segment (Hitrans) skyrocketed by 944.1% year-over-year to $27.98 million, up from $2.68 million in Q4 2024[2] - Full Year Consolidated Net Revenues reached $195.19 million, an 11% increase from $176.61 million in 2024[15] - Net Revenues from the Hitrans segment increased by 123% year-over-year to $89.21 million, compared to $40.03 million in 2024[17] - CBAK Energy reported net revenues of $195.19 million for the year ended December 31, 2025, an increase of 10.0% from $176.61 million in 2024[36] Profitability and Loss - Gross profit for the fourth quarter was $4.28 million, with a gross margin of 7.3%, down from a gross profit of $3.31 million and a margin of 13.1% in Q4 2024[10] - The company's gross profit decreased to $18.42 million in 2025, down from $41.78 million in 2024, reflecting a gross margin decline[36] - Operating loss for the fiscal year 2025 was $18.44 million, compared to an operating income of $8.79 million in 2024[22] - Operating income turned negative with a loss of $18.44 million in 2025, compared to a profit of $8.79 million in 2024[36] - The company reported a net loss attributable to shareholders of $9.38 million in 2025, compared to a profit of $11.79 million in 2024[36] Research and Development - Research and development (R&D) expenses in Q4 2025 rose to $5.30 million, compared to $3.80 million in Q4 2024[11] - Research and development expenses increased to $15.80 million in 2025, up from $13.01 million in 2024, indicating a focus on innovation[36] Assets and Liabilities - Cash and cash equivalents as of December 31, 2025, were $75.68 million, up from $60.79 million as of December 31, 2024[23] - Total current assets rose to $180.64 million in 2025, compared to $141.40 million in 2024, driven by increases in cash and inventories[33] - Total liabilities increased significantly to $316.70 million in 2025, up from $182.15 million in 2024, primarily due to higher trade payables[34] - CBAK Energy's total assets grew to $426.18 million in 2025, up from $302.22 million in 2024, reflecting expansion efforts[33] Capital Expenditures - Capital expenditures for 2025 were $44.65 million, primarily for the construction and equipping of new production facilities[23] Operational Footprint - The company has multiple operating subsidiaries and a large-scale R&D and production base in Dalian, indicating a strong operational footprint in China[27] - CBAK Energy is engaged in the development of new energy high power lithium and sodium batteries, targeting electric vehicles and energy storage applications[27]

Financial Performance - Total expenses increased from $5.76 million in 2024 to $13.20 million in 2025, representing a 129% increase[157]. - The net loss attributable to shareholders increased from $6.35 million in 2024 to $19.53 million in 2025, marking a 208% increase[157]. - The company experienced a loss of approximately $3.59 million on digital assets in 2025, with no digital assets held in 2024[170]. - The company expects to continue incurring net losses and negative cash flow from operations, raising substantial doubt regarding its ability to continue as a going concern[179]. Expenses Breakdown - General and administrative expenses rose from $4.20 million in 2024 to $8.82 million in 2025, primarily due to a $1.4 million increase in investor relation fees and a $3.0 million increase in consultant fees[158]. - Research and development expenses decreased significantly from $1.20 million in 2024 to $0.18 million in 2025, a reduction of approximately 85%[159]. - Credit loss expense for short-term note receivable surged from $0.36 million in 2024 to $4.20 million in 2025, attributed to Marizyme's debt increasing from $2.4 million to $4.9 million[160]. - Interest expense increased to $0.99 million in 2025 from $0.91 million in 2024, due to higher interest rates on short-term promissory notes[167]. Cash Flow and Financing Activities - Net cash used in operating activities was $7.0 million for the year ended December 31, 2025, primarily due to a loss from continuing operations of $16.9 million[191]. - Net cash used by investing activities was approximately $15.8 million in 2025, primarily due to purchases of digital assets totaling $16.5 million[193]. - Net cash provided by financing activities was $41.0 million in 2025, resulting from the issuance of preferred shares amounting to $38.9 million[195]. - The company raised approximately $45.7 million in new equity during the year ended December 31, 2025, compared to $9.0 million in 2024, highlighting a significant increase in financing activities[180]. Stock and Debt Transactions - Following a reverse stock split on November 5, 2024, the outstanding common stock increased by approximately 192% due to conversions of Series B Preferred Stock[154]. - The company recognized a gain of approximately $56,000 on the voluntary conversion of convertible debt into common stock during the year ended December 31, 2024, with a fair value of approximately $674,000 for 58,378 shares issued at a weighted average share price of $13.00[171]. - A loss on debt extinguishment of approximately $57,000 was recorded in 2024, primarily due to the repayment of the 2024 Alpha Debenture, resulting in a net loss of approximately $68,000 offset by a gain of approximately $13,000 from the issuance of Series A-2 Preferred Stock[172]. - The company issued 45,496 shares of common stock with a fair value of approximately $903,000 for monthly redemptions of $660,000 principal, resulting in a loss of approximately $209,000 during the year ended December 31, 2024[173]. - The company settled $395,000 of outstanding accounts payable for a gain of approximately $348,000 in 2024[174]. Financial Position - As of December 31, 2025, the company had approximately $19.3 million in cash and an accumulated deficit of $140.0 million, indicating a weak financial position[177].

Financial Performance - Enlight Renewable Energy Ltd. reported significant growth in revenue, with a year-over-year increase of 25% to $150 million[15] - Enlight projects a revenue growth of 20% for the next fiscal year, targeting $180 million[15] - The company achieved a total installed capacity of 1.5 GW, representing a 30% increase compared to the previous year[15] - User data indicates a 40% increase in customer base, reaching 500,000 users[15] Investment and Development - The company is investing $50 million in new technology development to enhance energy efficiency[15] - The company plans to launch two new renewable energy products in Q3 2024, expected to contribute an additional $30 million in revenue[15] - Enlight is exploring strategic acquisitions to bolster its portfolio, with a budget of $100 million allocated for potential mergers[15] - Market expansion efforts include entering three new states, aiming for a 15% market share in those regions by 2025[15] Operational Efficiency and Challenges - Enlight's operational efficiency improved, with a reduction in costs by 10% due to optimized supply chain management[15] - The company experienced project delays ranging from 6 to 24 months in 2025 due to regulatory reforms and extended reviews by regulators[65] - The company reported that several projects faced challenges in obtaining interconnection rights, which could significantly impact revenue and operational capacity[65] - The company is facing increased interconnection costs and longer approval times, which complicate project planning and could adversely affect the development pipeline[70] Regulatory and Compliance Risks - The company emphasizes its commitment to ESG standards, aligning with evolving regulatory requirements and stakeholder interests[15] - The company must navigate legal, regulatory, and compliance risks across multiple jurisdictions, which could affect operations and profitability[26] - The Uyghur Forced Labor Prevention Act may impact the supply chain, particularly concerning components sourced from the Xinjiang region of China, potentially leading to delays or increased costs[76] - The company must secure various governmental and environmental approvals, which are becoming more demanding and may delay project timelines[72] Market and Competitive Landscape - The company is subject to risks related to intense competition from traditional utilities and renewable energy companies in project development[25] - Competition in the renewable energy sector is intensifying, with traditional energy companies posing a threat to securing favorable offtake contracts[88] - Intense competition for offtake contracts may lead to downward pressure on pricing, adversely affecting revenue and financial performance[90] Financial Risks - The company is exposed to electricity price volatility, which could affect cash flows under certain offtake arrangements[25] - The company relies on a limited number of operational projects for a substantial portion of its cash flows, increasing financial risk[26] - The company is exposed to credit risk from offtakers, which could impact cash flows and financing for future projects if counterparties default[96] - The company may incur significant liquidated damages and penalties if it fails to complete renewable energy projects in accordance with contractual obligations[65] Environmental and Operational Risks - The company is subject to risks associated with the performance of solar and wind energy projects, including potential degradation of equipment and increased operational costs[102] - The company highlighted that electricity prices are volatile, influenced by factors such as new lower-cost generation plants and changes in demand, which could negatively impact financial results[114] - The company experienced operational disruptions and repair costs due to quality failures in turbine blades and other equipment, which may not be fully compensated under warranty agreements[108] - The company reported that severe weather and natural catastrophes could significantly reduce energy output, leading to decreased total revenues and increased operational costs[106] Cybersecurity and Data Management - The company experienced one cyber-related incident in 2024, classified as immaterial, causing no damage to its data or infrastructure[142] - Cybersecurity risks are expected to increase, with a growing number of intrusion attempts blocked by the company's defensive measures[142] - The company is subject to risks associated with litigation or administrative proceedings that could materially affect its operations and financial condition[138] Supply Chain and Material Costs - The company is subject to risks from fluctuating market prices of raw materials such as steel, aluminum, copper, and lithium, which could increase project costs[74] - The company's supply chain policy aims to mitigate the impact of tariffs by sourcing equipment from countries unaffected by trade restrictions[178] - Future tariffs could increase the price of solar systems in the U.S., potentially reducing demand and affecting gross margins[179] Debt and Financing - As of December 31, 2025, the company's consolidated indebtedness was approximately $4.8 billion, net of deferred financing costs[201] - The company had approximately $1.7 billion of consolidated variable-rate debt outstanding and $3.1 billion of fixed-rate debt outstanding as of December 31, 2025[198] - The company expects to rely heavily on third-party project financing, including tax equity arrangements, which may not be available in the future[205] - The cost of tax equity financing has increased and may continue to do so, potentially limiting the company's ability to develop and acquire additional assets[206]

Capital and Financing - Fermi America raised approximately $1.8 billion in capital since inception, with $935 million capitalized into property, plant, and equipment by December 31, 2025[6]. - The initial public offering (IPO) on October 1, 2025, raised $785 million at $21 per share, priced at the top of the range due to oversubscription[25]. - Year-to-date cash provided by financing activities was $1.0 billion, with significant contributions from the IPO ($745.6 million) and the issuance of Preferred Units ($107.6 million)[62]. Infrastructure Development - The company has contracted, financed, and delivered a multi-gigawatt generation pipeline, with power equipment on site, in transit, or in fabrication across three continents[17]. - Fermi's first six Siemens Energy SGT-800 turbines, rated at 478 MW, have arrived and are part of a broader strategy to deliver power at scale[21]. - The company has completed 11.3 miles of perimeter fencing and 4.6 miles of gas pipeline, with infrastructure capable of supporting approximately 2 GW of generation[41]. - Fermi has secured a grid connection agreement expected to deliver 86 MW upon initial energization, ramping to 1,000 MW[23]. Regulatory and Permitting - Fermi secured a Clean Air Permit for approximately 6 GW of natural gas generation, one of the largest permits ever issued for a private power project in the U.S.[30]. - The company has received a 6 GW clean air permit and plans to file for an additional 5 GW of capacity, with expectations to execute binding tenant agreements and begin vertical construction within the next twelve months[57][58]. - Fermi's nuclear program has progressed to the Nuclear Regulatory Commission (NRC) review stage, with a Combined Operating License Application filed for four Westinghouse AP1000 reactors[35]. Financial Performance - The company reported a year-to-date net loss of $486.4 million, primarily due to $441.8 million in non-cash charges, including a $173.8 million charitable contribution and $132.7 million in share-based compensation[59]. - Cash used in operating activities was $34.2 million, while cash used in investing activities totaled $570.3 million, mainly for early-stage development of Project Matador[60][61]. - Fermi holds approximately $1.4 billion in total assets, including $935.3 million in property, plant, and equipment, and $408.5 million in cash and cash equivalents as of December 31, 2025[64][65]. Market Position and Strategy - Eight covering analysts rate Fermi a Buy or Strong Buy, with an average price target of $29, indicating that the current share price does not reflect the company's built value[52]. - The commercial pipeline has expanded significantly, with active discussions with multiple prospective tenants, including hyperscale cloud operators and AI infrastructure companies[50]. - Fermi aims to secure a creditworthy anchor tenant to support project financing structures, which is crucial for unlocking non-recourse project debt and de-risking equity[51]. - The company is committed to long-term ownership and alignment with shareholders, with significant shareholders involved in the management team[56].

Financial Performance - Reviva reported a net loss of approximately $19.9 million, or $5.48 per share, for the fiscal year ended December 31, 2025, a decrease from a net loss of approximately $29.9 million, or $17.73 per share, for the fiscal year ended December 31, 2024[9][17]. - Total operating expenses for 2025 were $20.2 million, down from $30.8 million in 2024, with research and development expenses at $11.7 million compared to $22.9 million in the previous year[9][17]. - Reviva's total assets as of December 31, 2025, were approximately $15.9 million, compared to $15.5 million as of December 31, 2024[9][15]. Cash Position - As of December 31, 2025, the company's cash and cash equivalents totaled approximately $14.4 million, an increase from approximately $13.5 million as of December 31, 2024[9][15]. - The company has cash and cash equivalents of approximately $23 million following the March 2026 offering, which is expected to fund operations into Q1-2027[9][9]. Clinical Development - The company plans to initiate the RECOVER-2 registrational Phase 3 trial for brilaroxazine in mid-2026, with trial-related activities starting in Q2-2026 and patient enrollment in the U.S. expected to begin in Q3-2026[9][8]. - Brilaroxazine demonstrated robust efficacy in a one-year study, with a PANSS total score improvement of -18.1 and only <1% of patients reporting symptom relapse[9][6]. - The Phase 3 RECOVER trial data package includes a well-tolerated safety profile observed in over 900 subjects treated to date[9][6]. Funding Activities - The company completed public equity offerings in June 2025, September 2025, and March 2026, raising gross proceeds of $10.0 million, $9.0 million, and $10.0 million, respectively[9][9]. Intellectual Property - Reviva's patent portfolio includes a European Patent granted in November 2025 for the use of brilaroxazine in treating pulmonary fibrosis, expanding its protection in key markets[9][9].

Financial Performance - In Q4 2025, Sigma Lithium generated cash from operations of US$31 million, with cash inflows of US$41 million and operating costs of US$10 million[4]. - Sigma Lithium achieved net sales revenues of approximately US$67 million in Q4 2025 and Q1 2026, with sales of about 650,000 tonnes of high-purity lithium fines and approximately 5,000 tonnes of high-grade premium lithium oxide concentrate[9]. - The operating cash margin was 47% in Q4 2025, with a 77% year-over-year decline in operating costs offsetting a 64% drop in net sales revenues[10]. - Cash inflows for Q1 2026 were US$35 million, with cash and equivalents as of March 30, 2026, totaling US$12 million[5]. - The company reduced trade finance debt by 60% and total debt by 35% in 2025, with total debt at year-end 2025 standing at US$141 million[11]. Production and Sales Agreements - The company signed two offtake agreements totaling US$146 million, including US$96 million for 70,500 tonnes in 2026 and US$50 million for 40,000 tonnes per year for three years starting in 2026[6][8]. - Sigma Lithium expects to produce 240,000 tonnes of high-grade premium lithium oxide concentrate in the next twelve months at an all-in sustaining cost of US$592 per tonne[12]. - The company plans to continue its successful commercial strategy, benefiting from the flexibility in the timing of product delivery under the signed agreements[8]. Environmental Sustainability - Sigma Lithium's Greentech Industrial Plant emphasizes environmental sustainability, utilizing 100% renewable electricity and zero toxic chemicals[15]. - The company is undergoing a Phase 2 expansion to nearly double its production capacity to 520,000 tonnes annually[16].

Financial Performance - The loss for Kazia Therapeutics Limited for the half-year ended 31 December 2025 was $12,552,490, compared to a loss of $10,453,811 for the same period in 2024, representing an increase of approximately 20%[4] - The total comprehensive loss for the half-year was $13,412,383, compared to $10,279,476 in the previous year, reflecting an increase of approximately 30%[29] - Kazia Therapeutics reported a loss after income tax of $12,552,490 for the half-year ended December 31, 2025, compared to a loss of $10,453,811 for the same period in 2024, representing an increase of approximately 20%[38] - The basic loss per share for December 2025 was (0.805) cents, a decrease from (2.459) cents in December 2024[77] Cash and Funding - Total cash resources at 31 December 2025 amounted to $69,459,980, a significant increase from $4,344,691 at 30 June 2025[6][30] - The company raised $46.51 million through a PIPE transaction on 2 December 2025, contributing to the current cash balance[9] - The company raised $65,248,181 through the issuance of shares during the half-year, significantly up from $16,387,602 in the previous half-year[32] - Cash and cash equivalents at the end of the financial half-year stood at $69,459,980, a substantial increase from $4,344,691 at the beginning of the period[32] - The net proceeds from the December 2025 PIPE were US$46.51 million after deducting offering expenses, with 4,530,854,000 ordinary shares sold at a price of $0.01 per share[54] - The company raised total proceeds of US$1,397,016 using the ATM facility from July to December 2025, with a remaining capacity of US$35.19 million[61] Research and Development - Research and development expenses for the half-year were $4,992,238, up from $4,282,101 in the previous year, indicating a year-over-year increase of approximately 17%[29] - Kazia Therapeutics expanded its clinical development of paxalisib into multiple breast cancer settings, including a Phase 1b study in metastatic triple-negative breast cancer[10] - The company reported an 86% reduction in overall tumor burden in a case treated with a combination immunotherapy/chemotherapy regimen plus paxalisib[13] Compliance and Governance - The company regained compliance with Nasdaq listing standards on 18 December 2025, ensuring continued trading of its ADSs[9] - The company continued to comply with Nasdaq listing requirements, regaining compliance with the minimum market value of listed securities[39] - The directors are responsible for preparing the half-year financial report in accordance with Australian Accounting Standards and the Corporations Act 2001[85] - The financial report must give a true and fair view of the Group's financial position as of December 31, 2025, and its performance for the half-year ended on that date[87] - The auditor's responsibility includes expressing a conclusion on the half-year financial report based on a review, not an audit, which is less comprehensive[89] Assets and Liabilities - The net current asset position improved to $45,612,689 as of 31 December 2025, compared to a net current liability of $9,119,727 at 30 June 2025[7] - The company had a net current asset position of $45,612,689 as of December 31, 2025, a significant improvement from a net current liability of $9,119,727 as of June 30, 2025[38] - Trade payables increased to $6,127,338 from $5,644,797, reflecting higher operational liabilities[49] - Employee benefits provisions increased to US$445,975 in December 2025 from US$426,786 in June 2025[57] - The foreign currency translation reserve showed a negative balance of US$1,633,404 in December 2025, compared to a negative balance of US$773,511 in June 2025[73] - The share-based payments reserve increased to US$6,737,860 in December 2025 from US$3,873,198 in June 2025[73] - The deferred tax liability associated with the licensing agreement remained unchanged at US$271,629 from June 2025 to December 2025[58] Employee Compensation - Kazia Therapeutics' employee share-based payment expense increased to $4,634,705 for the half-year, compared to $290,053 in the previous year[42] - The company incurred transaction costs of A$5,278,293 related to the PIPE, allocated between equity and derivative liability components[54]